Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis

Debayan Dasgupta, Mark J. Wee, Monica Reyes, Yuwen Li, Peter J. Simm, Amita Sharma, Karl Peter Schlingmann, Marco Janner, Andrew Biggin, Joanna Lazier, Michaela Gessner, Dionisios Chrysis, Shamir Tuchman, H. Jorge Baluarte, Michael A. Levine, Dov Tiosano, Karl Insogna, David A. Hanley, Thomas O. Carpenter, Shoji IchikawaBernd Hoppe, Martin Konrad, Lars Sävendahl, Craig F. Munns, Hang Lee, Harald Jüppner, Clemens Bergwitz

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Compound heterozygous and homozygous (comp/hom) mutations in solute carrier family 34, member 3 (SLC34A3), the gene encoding the sodium (Na+)-dependent phosphate cotransporter 2c (NPT2c), cause hereditary hypophosphatemic rickets with hypercalciuria (HHRH), a disorder characterized by renal phosphate wasting resulting in hypophosphatemia, correspondingly elevated 1,25(OH)2 vitamin D levels, hypercalciuria, and rickets/osteomalacia. Similar, albeit less severe, biochemical changes are observed in heterozygous (het) carriers and indistinguishable fromthose changes encountered in idiopathic hypercalciuria (IH). Here, we report a review of clinical and laboratory records of 133 individuals from 27 kindreds, including 5 previously unreported HHRH kindreds and two cases with IH, in which known and novel SLC34A3 mutations (c.1357delTTC [p.F453del]; c.G1369A [p.G457S]; c.367delC) were identified. Individuals with mutations affecting both SLC34A3 alleles had a significantly increased risk of kidney stone formation or medullary nephrocalcinosis, namely 46%compared with 6%observed in healthy family members carrying only the wild-type SLC34A3 allele (P=0.005) or 5.64% in the general population (P<0.001). Renal calcifications were also more frequent in het carriers (16%; P=0.003 compared with the general population) and were more likely to occur in comp/hom and het individuals with decreased serum phosphate (odds ratio [OR], 0.75, 95% confidence interval [95%CI], 0.59 to 0.96; P=0.02), decreased tubular reabsorption of phosphate (OR, 0.41; 95%CI, 0.23 to 0.72; P=0.002), and increased serum 1,25(OH)2 vitamin D(OR, 1.22;95%CI, 1.05 to 1.41; P=0.008). Additional studies are needed to determine whether these biochemical parameters are independent of genotype and can guide therapy to prevent nephrocalcinosis, nephrolithiasis, and potentially, CKD.

Original languageEnglish
Pages (from-to)2366-2375
Number of pages10
JournalJournal of the American Society of Nephrology
Volume25
Issue number10
DOIs
StatePublished - Oct 1 2014

Fingerprint

Nephrocalcinosis
Kidney Calculi
Hypercalciuria
Phosphates
Ergocalciferols
Mutation
Odds Ratio
Confidence Intervals
Alleles
Hypophosphatemia
Kidney
Nephrolithiasis
Osteomalacia
Rickets
Serum
Population
Sodium
Genotype
Genes
Hereditary Hypophosphatemic Rickets with Hypercalciuria

ASJC Scopus subject areas

  • Nephrology
  • Medicine(all)

Cite this

Dasgupta, D., Wee, M. J., Reyes, M., Li, Y., Simm, P. J., Sharma, A., ... Bergwitz, C. (2014). Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis. Journal of the American Society of Nephrology, 25(10), 2366-2375. https://doi.org/10.1681/ASN.2013101085

Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis. / Dasgupta, Debayan; Wee, Mark J.; Reyes, Monica; Li, Yuwen; Simm, Peter J.; Sharma, Amita; Schlingmann, Karl Peter; Janner, Marco; Biggin, Andrew; Lazier, Joanna; Gessner, Michaela; Chrysis, Dionisios; Tuchman, Shamir; Baluarte, H. Jorge; Levine, Michael A.; Tiosano, Dov; Insogna, Karl; Hanley, David A.; Carpenter, Thomas O.; Ichikawa, Shoji; Hoppe, Bernd; Konrad, Martin; Sävendahl, Lars; Munns, Craig F.; Lee, Hang; Jüppner, Harald; Bergwitz, Clemens.

In: Journal of the American Society of Nephrology, Vol. 25, No. 10, 01.10.2014, p. 2366-2375.

Research output: Contribution to journalArticle

Dasgupta, D, Wee, MJ, Reyes, M, Li, Y, Simm, PJ, Sharma, A, Schlingmann, KP, Janner, M, Biggin, A, Lazier, J, Gessner, M, Chrysis, D, Tuchman, S, Baluarte, HJ, Levine, MA, Tiosano, D, Insogna, K, Hanley, DA, Carpenter, TO, Ichikawa, S, Hoppe, B, Konrad, M, Sävendahl, L, Munns, CF, Lee, H, Jüppner, H & Bergwitz, C 2014, 'Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis', Journal of the American Society of Nephrology, vol. 25, no. 10, pp. 2366-2375. https://doi.org/10.1681/ASN.2013101085
Dasgupta, Debayan ; Wee, Mark J. ; Reyes, Monica ; Li, Yuwen ; Simm, Peter J. ; Sharma, Amita ; Schlingmann, Karl Peter ; Janner, Marco ; Biggin, Andrew ; Lazier, Joanna ; Gessner, Michaela ; Chrysis, Dionisios ; Tuchman, Shamir ; Baluarte, H. Jorge ; Levine, Michael A. ; Tiosano, Dov ; Insogna, Karl ; Hanley, David A. ; Carpenter, Thomas O. ; Ichikawa, Shoji ; Hoppe, Bernd ; Konrad, Martin ; Sävendahl, Lars ; Munns, Craig F. ; Lee, Hang ; Jüppner, Harald ; Bergwitz, Clemens. / Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis. In: Journal of the American Society of Nephrology. 2014 ; Vol. 25, No. 10. pp. 2366-2375.
@article{6e9f977978914ffaa1119daf4b044743,
title = "Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis",
abstract = "Compound heterozygous and homozygous (comp/hom) mutations in solute carrier family 34, member 3 (SLC34A3), the gene encoding the sodium (Na+)-dependent phosphate cotransporter 2c (NPT2c), cause hereditary hypophosphatemic rickets with hypercalciuria (HHRH), a disorder characterized by renal phosphate wasting resulting in hypophosphatemia, correspondingly elevated 1,25(OH)2 vitamin D levels, hypercalciuria, and rickets/osteomalacia. Similar, albeit less severe, biochemical changes are observed in heterozygous (het) carriers and indistinguishable fromthose changes encountered in idiopathic hypercalciuria (IH). Here, we report a review of clinical and laboratory records of 133 individuals from 27 kindreds, including 5 previously unreported HHRH kindreds and two cases with IH, in which known and novel SLC34A3 mutations (c.1357delTTC [p.F453del]; c.G1369A [p.G457S]; c.367delC) were identified. Individuals with mutations affecting both SLC34A3 alleles had a significantly increased risk of kidney stone formation or medullary nephrocalcinosis, namely 46{\%}compared with 6{\%}observed in healthy family members carrying only the wild-type SLC34A3 allele (P=0.005) or 5.64{\%} in the general population (P<0.001). Renal calcifications were also more frequent in het carriers (16{\%}; P=0.003 compared with the general population) and were more likely to occur in comp/hom and het individuals with decreased serum phosphate (odds ratio [OR], 0.75, 95{\%} confidence interval [95{\%}CI], 0.59 to 0.96; P=0.02), decreased tubular reabsorption of phosphate (OR, 0.41; 95{\%}CI, 0.23 to 0.72; P=0.002), and increased serum 1,25(OH)2 vitamin D(OR, 1.22;95{\%}CI, 1.05 to 1.41; P=0.008). Additional studies are needed to determine whether these biochemical parameters are independent of genotype and can guide therapy to prevent nephrocalcinosis, nephrolithiasis, and potentially, CKD.",
author = "Debayan Dasgupta and Wee, {Mark J.} and Monica Reyes and Yuwen Li and Simm, {Peter J.} and Amita Sharma and Schlingmann, {Karl Peter} and Marco Janner and Andrew Biggin and Joanna Lazier and Michaela Gessner and Dionisios Chrysis and Shamir Tuchman and Baluarte, {H. Jorge} and Levine, {Michael A.} and Dov Tiosano and Karl Insogna and Hanley, {David A.} and Carpenter, {Thomas O.} and Shoji Ichikawa and Bernd Hoppe and Martin Konrad and Lars S{\"a}vendahl and Munns, {Craig F.} and Hang Lee and Harald J{\"u}ppner and Clemens Bergwitz",
year = "2014",
month = "10",
day = "1",
doi = "10.1681/ASN.2013101085",
language = "English",
volume = "25",
pages = "2366--2375",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "10",

}

TY - JOUR

T1 - Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis

AU - Dasgupta, Debayan

AU - Wee, Mark J.

AU - Reyes, Monica

AU - Li, Yuwen

AU - Simm, Peter J.

AU - Sharma, Amita

AU - Schlingmann, Karl Peter

AU - Janner, Marco

AU - Biggin, Andrew

AU - Lazier, Joanna

AU - Gessner, Michaela

AU - Chrysis, Dionisios

AU - Tuchman, Shamir

AU - Baluarte, H. Jorge

AU - Levine, Michael A.

AU - Tiosano, Dov

AU - Insogna, Karl

AU - Hanley, David A.

AU - Carpenter, Thomas O.

AU - Ichikawa, Shoji

AU - Hoppe, Bernd

AU - Konrad, Martin

AU - Sävendahl, Lars

AU - Munns, Craig F.

AU - Lee, Hang

AU - Jüppner, Harald

AU - Bergwitz, Clemens

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Compound heterozygous and homozygous (comp/hom) mutations in solute carrier family 34, member 3 (SLC34A3), the gene encoding the sodium (Na+)-dependent phosphate cotransporter 2c (NPT2c), cause hereditary hypophosphatemic rickets with hypercalciuria (HHRH), a disorder characterized by renal phosphate wasting resulting in hypophosphatemia, correspondingly elevated 1,25(OH)2 vitamin D levels, hypercalciuria, and rickets/osteomalacia. Similar, albeit less severe, biochemical changes are observed in heterozygous (het) carriers and indistinguishable fromthose changes encountered in idiopathic hypercalciuria (IH). Here, we report a review of clinical and laboratory records of 133 individuals from 27 kindreds, including 5 previously unreported HHRH kindreds and two cases with IH, in which known and novel SLC34A3 mutations (c.1357delTTC [p.F453del]; c.G1369A [p.G457S]; c.367delC) were identified. Individuals with mutations affecting both SLC34A3 alleles had a significantly increased risk of kidney stone formation or medullary nephrocalcinosis, namely 46%compared with 6%observed in healthy family members carrying only the wild-type SLC34A3 allele (P=0.005) or 5.64% in the general population (P<0.001). Renal calcifications were also more frequent in het carriers (16%; P=0.003 compared with the general population) and were more likely to occur in comp/hom and het individuals with decreased serum phosphate (odds ratio [OR], 0.75, 95% confidence interval [95%CI], 0.59 to 0.96; P=0.02), decreased tubular reabsorption of phosphate (OR, 0.41; 95%CI, 0.23 to 0.72; P=0.002), and increased serum 1,25(OH)2 vitamin D(OR, 1.22;95%CI, 1.05 to 1.41; P=0.008). Additional studies are needed to determine whether these biochemical parameters are independent of genotype and can guide therapy to prevent nephrocalcinosis, nephrolithiasis, and potentially, CKD.

AB - Compound heterozygous and homozygous (comp/hom) mutations in solute carrier family 34, member 3 (SLC34A3), the gene encoding the sodium (Na+)-dependent phosphate cotransporter 2c (NPT2c), cause hereditary hypophosphatemic rickets with hypercalciuria (HHRH), a disorder characterized by renal phosphate wasting resulting in hypophosphatemia, correspondingly elevated 1,25(OH)2 vitamin D levels, hypercalciuria, and rickets/osteomalacia. Similar, albeit less severe, biochemical changes are observed in heterozygous (het) carriers and indistinguishable fromthose changes encountered in idiopathic hypercalciuria (IH). Here, we report a review of clinical and laboratory records of 133 individuals from 27 kindreds, including 5 previously unreported HHRH kindreds and two cases with IH, in which known and novel SLC34A3 mutations (c.1357delTTC [p.F453del]; c.G1369A [p.G457S]; c.367delC) were identified. Individuals with mutations affecting both SLC34A3 alleles had a significantly increased risk of kidney stone formation or medullary nephrocalcinosis, namely 46%compared with 6%observed in healthy family members carrying only the wild-type SLC34A3 allele (P=0.005) or 5.64% in the general population (P<0.001). Renal calcifications were also more frequent in het carriers (16%; P=0.003 compared with the general population) and were more likely to occur in comp/hom and het individuals with decreased serum phosphate (odds ratio [OR], 0.75, 95% confidence interval [95%CI], 0.59 to 0.96; P=0.02), decreased tubular reabsorption of phosphate (OR, 0.41; 95%CI, 0.23 to 0.72; P=0.002), and increased serum 1,25(OH)2 vitamin D(OR, 1.22;95%CI, 1.05 to 1.41; P=0.008). Additional studies are needed to determine whether these biochemical parameters are independent of genotype and can guide therapy to prevent nephrocalcinosis, nephrolithiasis, and potentially, CKD.

UR - http://www.scopus.com/inward/record.url?scp=84921797873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921797873&partnerID=8YFLogxK

U2 - 10.1681/ASN.2013101085

DO - 10.1681/ASN.2013101085

M3 - Article

C2 - 24700880

AN - SCOPUS:84921797873

VL - 25

SP - 2366

EP - 2375

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 10

ER -